Our Rapid Diagnostics Centre offers fast access to advanced imaging, specialist clinics and on-site testing - helping you get clarity in days, not weeks. Plus, our 24/7 private GP service is here whenever you need urgent advice.
As a charitable hospital, we reinvest in exceptional care, research and innovation - helping us improve healthcare for patients here and far beyond our walls.
Your Patient Hub brings together everything you need to prepare for your visit, understand your care and know what to expect throughout your stay.
25 June 2024
The treatment developed by German-based company OncoBeta ®, uses the chemical element rhenium to deliver a controlled dosage of radiation to the skin surface, treating superficial skin cancers precisely and painlessly. Results are impressive, showing complete tumour regression in 98.5% of lesions treated.
“The treatment is designed for non-melanoma skin cancer, which is an abnormal growth of cells that usually (but not always) develops on an area of skin that has been highly exposed to the sun. It grows more slowly than melanoma and is less likely to spread. However, it still requires treatment to stop it growing and possibly spreading.”
-Dr. Gerhard Dahlhoff, Medical Director for OncoBeta ®.
Following a Dermatologist referral, patients will be able to come to The London Clinic to be assessed by the radiation specialist, and then booked in for this treatment from 26 June 2024. Patients without a Dermatologist referral can still access this treatment if suitable by booking an appointment in the Dermatology Clinic at The London Clinic’s Rapid Diagnostics Centre.
The treatment will begin with the dermatologist marking the required area, after which the nuclear medicine specialist can then apply a radioactive paste to the skin surface. The treatment takes approximately 30 to 180 minutes depending on the size and depth of the area needed to treat. Once the paste is removed, the procedure is complete and patients can go home.
This is a very exciting treatment because it’s non-invasive, completely painless and does not require any anaesthetic or surgery. In most cases only one treatment session is required, and the patient can literally walk in and walk out. Most treatments for skin cancer require a surgical procedure and a degree of aftercare or wound care, such as stitches or dressings. No aftercare is needed for the Rhenium-SCT® treatment.The London Clinic’s Consultant Dermatologist Dr Bashir.
Rhenium-SCT® can treat any non-melanoma skin cancer. Its particular advantages lie in the treatment of patients with multiple lesions at one time, since no serious side effects are to be expected due to the low depth of action. It’s also good for elderly patients, those with allergies, comorbidities or a low pain tolerance, and is recommended for those with tumors in high-risk or difficult to treat areas, where surgery has been refused, cases where surgery would result in functional mutilation cases where relapse has occurred, and for patients who have been diagnosed with either basal cell carcinoma or squamous cell carcinoma.
OncoBeta® with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specialising in the development and commercialisation of state-of-the-art, innovative therapies. Since its foundation, OncoBeta® has concentrated its efforts on the development, regulatory approval(s) and commercialisation of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. OncoBeta® has perfected the customised application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
